Literature DB >> 34535789

The FDA's latest move to expand eligibility for oncology trials - a double-edged sword?

Mark P Lythgoe1, Vinay Prasad2.   

Abstract

Entities:  

Mesh：

Year:  2021        PMID： 34535789     DOI： 10.1038/s41571-021-00559-0

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  The Oncologic Drugs Advisory Committee Votes of April 2021-Implications for the Fate of Accelerated Approval.

Authors:  Kerrington Powell; Mark P Lythgoe; Vinay Prasad
Journal:  JAMA Oncol       Date:  2021-11-01       Impact factor: 31.777
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.